GM1 gangliosidosis is a lysosomal storage disease caused by mutations in the human GLB1 gene, encoding the ubiquitous lysosomal β-galactosidase. GM1 causes a rapidly progressing neurodegeneration, which can be lethal in the first 2 years of life in the most severe cases.
Researchers from Sab Biotherapeutics Inc. presented data generated in the development and validation of a pharmacokinetic (PK) assay for SAB-142 and the evaluation of its toxicology and immunologic effects in a juvenile cynomolgus monkey model.
Terns Pharmaceuticals Inc. has synthesized glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of diabetes, obesity, liver diseases and cardiometabolic syndrome.
Pfizer Inc. has identified 4-{4-[(1-{[4-(propan-2-yl)phenyl]carbamoyl)-D-prolyl)amino]cyclohexyl}benzoic acid derivatives acting as gastric inhibitory polypeptide receptor (GIPR) antagonists. As such, they are described as potentially useful for the treatment of type 2 diabetes and obesity.
In a recent publication in Biomedicine & Pharmacotherapy, investigators evaluated the activity of a 7-amino-acid peptide, EB-203, using a zebrafish model of diabetic retinopathy (DR)-like vascular alterations.
Recent findings have shown that fatty acid synthase (FASN) is a promising therapeutic target in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD) due to its involvement in de novo lipogenesis. Chinese researchers have recently published data on a FASN inhibitor, 84-B10, for the potential treatment of MASLD.
Newcelx Ltd. has entered into a collaborative research agreement with Eledon Pharmaceuticals Inc. with the aim of advancing its lead program, NCEL-101, for type 1 diabetes.
China Medical System Holdings Ltd. has received clinical trial approval from China’s National Medical Products Administration (NMPA) for CMS-D008 injection for overweight or obese individuals.
RSS
